1. Home
  2. HOUR vs RLYB Comparison

HOUR vs RLYB Comparison

Compare HOUR & RLYB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Hour Loop Inc.

HOUR

Hour Loop Inc.

HOLD

Current Price

$1.82

Market Cap

77.4M

ML Signal

HOLD

Logo Rallybio Corporation

RLYB

Rallybio Corporation

HOLD

Current Price

$15.95

Market Cap

92.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
HOUR
RLYB
Founded
2015
2018
Country
United States
United States
Employees
N/A
N/A
Industry
Catalog/Specialty Distribution
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
77.4M
92.3M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
HOUR
RLYB
Price
$1.82
$15.95
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
63.6K
37.4K
Earning Date
05-13-2026
05-11-2026
Dividend Yield
N/A
N/A
EPS Growth
150.00
N/A
EPS
0.02
N/A
Revenue
$142,440,236.00
$858,000.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
$92.00
N/A
Revenue Growth
3.03
43.00
52 Week Low
$1.24
$0.39
52 Week High
$6.84
$17.57

Technical Indicators

Market Signals
Indicator
HOUR
RLYB
Relative Strength Index (RSI) 45.56 57.94
Support Level $1.75 $15.59
Resistance Level $2.12 $17.57
Average True Range (ATR) 0.15 0.43
MACD -0.00 -0.15
Stochastic Oscillator 19.40 24.73

Price Performance

Historical Comparison
HOUR
RLYB

About HOUR Hour Loop Inc.

Hour Loop Inc is a technology-enabled consumer products company that uses machine learning and data analytics to design, develop, market, and sell products. Hour Loop predominantly operates through online retail channels such as Amazon, Walmart, and Hourloop.com. The company, as an Internet marketplace seller, sells products in multiple categories, including home/garden decor, toys, kitchenware, apparel, and electronics. It has only one segment, which is online retail (e-commerce).

About RLYB Rallybio Corporation

Rallybio Corp is a clinical-stage biotechnology company comprised of experienced biopharma industry leaders with extensive research, development, and rare disease expertise with a mission to develop and commercialize life-transforming therapies for patients with severe and rare diseases. The company's program, RLYB116, is a differentiated complement component 5 (C5) inhibitor with the potential to treat diseases of complement dysregulation. The Company manages its operations as a single segment for the purposes of allocating resources, assessing performance, and making operating decisions. Rallybio's pipeline also includes RLYB332, a preclinical long-acting matriptase-2 antibody for the treatment of diseases of iron overload.

Share on Social Networks: